The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Open accessAbstract
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR. All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M. These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2009, Pasi et al. identified a series of covalent pyrimidine EGFR inhibitors, including WZ 3146, WZ 4002, and WZ 8040, through screening a library of irreversible kinase inhibitors specific to EGFRT790M.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [203]
In the citing paper
“These agents are designed to specifically inhibit mutant EGFR (ie, 19del-EGFR, L858R-EGFR and/or T790M+EGFR), sparing the WT receptor.14–18”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [14]
In the citing paper
“The presence of the T790M mutation was observed in approximately 50% of the cases in which biopsy was obtained at the time of relapse following gefitinib or erlotinib treatment in patients with the exon 19 deletion or the L858R EGFR mutation.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [14]
In the citing paper
“AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [34]
In the citing paper
“C797 is located opposite T790 in the ATP binding pocket and forms a covalent bond with all third-generation TKIs and is necessary for the inhibitor to suppress EGFR (21).”
In the citing paper
“This approach has previously led to identification of clinically relevant drug resistance mutations to EGFR TKIs (30, 31).”
From Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors (2017) · cites this paper as [30]
In the citing paper
“Thus, the T790M structural alteration in essence “enabled” discovery of inhibitors that selectively inhibit T790M–bearing mutants, when in association with L858R or exon 19 deletions, relative to WT EGFR 58,59.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [58]
In the citing paper
“Examination of the crystal structure of WZ4002 in complex with EGFR T790M (14) reveals that both L718 and L844 are in direct contact with the inhibitor; L718 primarily with the aniline ring and L844 with the pyrimidine ring (Figure 2A).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“Cysteine 797 is the site of covalent binding for all three of these agents (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“They are not only more potent on EGFR T790M, but also selectively inhibit mutant over WT EGFR and hence should lead to increased clinical efficacy and less toxicity compared with afatinib (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“C797 is the site of covalent binding of WZ4002 and previously demonstrated to lead to drug resistance if mutated to serine (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“CO-1686 is structurally more closely related to WZ4002 than to AZD9291 and in all of the models tested CO-1686 is very similar in vitro to WZ4002 (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“However, ENU mutagenesis studies have been predictive of clinical drug resistance mutations in several prior studies (14, 24).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“In prior studies, introduction of C797S into the background of EGFR L858R/T790M or EGFR Del 19/T790M resulted in significant loss of cellular potency for WZ4002 (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“Analogously, a non-covalent analogue of WZ4002, WZ4003, was ineffective in in vitro models of EGFR T790M (14).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“These include the development of mutant selective EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, which to date have demonstrated encouraging efficacy in both preclinical models and in EGFR mutant NSCLC patients with EGFR T790M mediated drug resistance (14–18).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [14]
In the citing paper
“WZ4002 is a covalent pyrimidine EGFR inhibitor specifically designed against EGFR T790M that is 30–100 fold more potent against EGFR T790M, and up to 100 fold less potent against wild type EGFR than quinazoline based EGFR inhibitors in vitro and is effective in murine models of lung cancer driven by EGFR T790M [84].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [84]
In the citing paper
“Both 2G and 3G EGFR‐TKI are irreversible small‐molecule inhibitors that covalently bind to EGFR kinase by targeting the cysteine‐797 residue, located in the ATP binding pocket, and 3G EGFR‐TKI are considered to be more specific for EGFR sensitizing mutations than 2G EGFR‐TKI.12, 13, 14”
In the citing paper
“A third generation of EGFR inhibitors followed afatinib; these covalent inhibitors selectively target the T790M mutant over wild-type EGFR, and include WZ4002 (Dana–Farber Cancer Institute)43, osimertinib44,45 and rociletinib (Clovis Oncology; CO-1686)46 (Fig. 2c).”
From Advances in covalent drug discovery (2022) · cites this paper as [43]
In the citing paper
“Standard of care is rapidly changing with the development of third-generation, mutant-selective EGFR-TKIs that have activity against cells that harbor TKI-sensitive EGFR mutations. Unlike conventional EGFR-TKIs, this activity is maintained in the presence of T790M resistance mutation.8,9”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [9]
In the citing paper
“Next-generation EGFR TKIs have since been developed specifically to target the T790M mutation, 17,18 and they have demonstrated high and durable responses in patients with advanced EGFRmutant NSCLC who have been previously treated and in whom firstor second-generation EGFR TKIs have failed.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Self-citationBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Self-citationEngelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,000
Li, Y., Song, Z., Jin, Y., Tang, Z., Kang, J., & Ma, X. (2016) · Molecules · doi:10.3390/molecules21111462 · Cited by 18
Tanaka, H., Sakagami, H., Kaneko, N., Konagai, S., Yamamoto, H., Matsuya, T., Yuri, M., Yamanaka, Y., Mori, M., Takeuchi, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0976 · Cited by 18
Qin, M., Wang, T., Xu, B., Ma, Z., Jiang, N., Xie, H., Gong, P., & Zhao, Y. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.031 · Cited by 17
Takeuchi, S., & Yano, S. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.10.002 · Cited by 17
Role of protein flexibility in the discovery of new drugs
Fuentes, G., Dastidar, S. G., Madhumalar, A., & Verma, C. S. (2010) · Drug Development Research · doi:10.1002/ddr.20399 · Cited by 18
Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
Zhang, C., Wei, B., Li, P., Yang, K., Wang, Z., Ma, J., & Guo, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173524 · Cited by 17
A Chemical-Genetic Approach to Generate Selective Covalent Inhibitors of Protein Kinases
Kung, A., Schimpl, M., Ekanayake, A. I., Chen, Y., Overman, R., & Zhang, C. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01083 · Cited by 17
Newman, J. H., Augeri, D. J., NeMoyer, R. E., Malhotra, J. D., Langenfeld, E. M., Chesson, C. B., Dobias, N. S., Lee, M. J., Tarabichi, S., Jhawar, S. R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0156-9 · Cited by 17
Zhao, Y. H., Jiao, Y., Sun, F., & Liu, X. (2018) · Medicinal Chemistry Research · doi:10.1007/s00044-018-2224-7 · Cited by 17
A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
Fawwaz, M., Mishiro, K., Nishii, R., Makino, A., Kiyono, Y., Shiba, K., Kinuya, S., & Ogawa, K. (2021) · Pharmaceuticals · doi:10.3390/ph14030256 · Cited by 17
Castelli, R., Bozza, N., Cavazzoni, A., Bonelli, M. A., Vacondio, F., Ferlenghi, F., Callegari, D., Silva, C., Rivara, S., Lodola, A., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.029 · Cited by 17
Targeting TAK1: Evolution of inhibitors, challenges, and future directions
Benedik, N. S., Proj, M., Steinebach, C., Sova, M., & Sosič, I. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108810 · Cited by 17
Winning the Arms Race by Improving Drug Discovery against Mutating Targets
Anderson, A. C. (2011) · ACS Chemical Biology · doi:10.1021/cb200394t · Cited by 16
Sun, J., & Park, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000350 · Cited by 16
Xu, J., Zhao, X., He, D., Wang, J., Li, W., Liu, Y., Ma, L., Jiang, M., Yu, T., Wang, Z., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2668-7 · Cited by 16
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
Combarel, D., Dousset, L., Bouchet, S., Ferrer, F., Tétu, P., Lebbé, C., Ciccolini, J., Meyer, N., & Paci, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104384 · Cited by 16
Wittlinger, F., Chitnis, S. P., Pham, C. D., Damghani, T., Patel, K. B., Möllers, M., Schaeffner, I. K., Abidakun, O. A., Deng, M. Q., Ogboo, B. C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02311 · Cited by 16
Self-citationRosell, R., Vergnenégre, A., Liu, B., Cobo, M., Massutí, B., Wei, J., Molina‐Vila, M. Á., Costa, C., Queralt, C., & Tarón, M. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.05.003 · Cited by 16
Dimou, A., Harrington, K. J., & Syrigos, K. (2011) · Pathology Research International · doi:10.4061/2011/312346 · Cited by 16
Ku, B. M., Bae, Y.-H., Koh, J., Sun, J., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0350-y · Cited by 16
Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 16
Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors
Hou, W., Sun, H., Ma, Y., Liu, C., & Zhang, Z. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00631 · Cited by 16
The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies
Attili, I., Re, M. D., Guerini‐Rocco, E., Crucitta, S., Pisapia, P., Pepe, F., Barberis, M. C. P., Troncone, G., Danesi, R., de Marinis, F., et al. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1943365 · Cited by 17
Chang, Y., Kim, S. Y., Choi, Y. J., So, K. S., Rho, J. K., Kim, W. S., Lee, J. C., Chung, J.-H., & Choi, C. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.75.3.95 · Cited by 16
Bailey, F. P., Andreev, V. I., & Eyers, P. A. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-397918-6.00005-7 · Cited by 16
Wintgens, J. P., Wichert, S. P., Popović, L., Rossner, M. J., & Wehr, M. C. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-03003-2 · Cited by 16
Francaviglia, I., Magliacane, G., Lazzari, C., Grassini, G., Brunetto, E., Cin, E. D., Girlando, S., Medicina, D., Smart, C. E., Bulotta, A., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.010 · Cited by 16
Xu, Y., Zhang, F., Pan, X., Wang, G., Zhu, L., Zhang, J., Wen, D., & Lu, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0284-1 · Cited by 16
PGxMine: Text mining for curation of PharmGKB
Lever, J., Barbarino, J. M., Gong, L., Huddart, R., Sangkuhl, K., Whaley, R., Whirl-Carrillo, M., Woon, M., Klein, T. E., & Altman, R. B. (2019) · Biocomputing 2020 · doi:10.1142/9789811215636_0054 · Cited by 16
Exploring the Anticancer Properties of Quinoxaline‐Based Molecules: A Systematic Review
Abdelall, E. K. A., Elshemy, H. A. H., Ryad, N., & Abdelaziz, A. A. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501173 · Cited by 15
El-Hema, H. S., Shehata, H. E., Hawata, M. A., Nossier, E. S., El-Sayed, A. F., Altwaijry, N., Saleh, A., Hussein, M. F., Sabry, A., & Abdel‐Rahman, A. A. ‐. (2025) · Pharmaceuticals · doi:10.3390/ph18101472 · Cited by 15
Sreedurgalakshmi, K., Srikar, R., & Rajkumari, R. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00256-7 · Cited by 16
Kawabata, S., Hollander, M. C., Munasinghe, J., Brinster, L., Mercado-Matos, J., Li, J., Regales, L., Pao, W. J., Janne, P. A., Wong, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3605 · Cited by 15
Self-citationXiang, M., Lei, K., Fan, W., Lin, Y., He, G., Yang, M., Chen, L., & Mo, Y. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s41305 · Cited by 15
Self-citationWang, Y., Guo, Z., Yang, L., & Zhou, Q. (2016) · Open Medicine · doi:10.1515/med-2016-0014 · Cited by 16
Song, A., Zhang, J., Yang, G., Wang, C., Meng, Q., Tang, Z., Peng, J., Liu, K., Li, Y., & Ma, X. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.032 · Cited by 15
Hu, J., Han, Y., Wang, J., Liu, Y., Zhao, Y., Liu, Y., & Gong, P. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.029 · Cited by 16
Oncogene Addicted Non-Small-Cell Lung Cancer: Current Standard and Hot Topics
Vecchiarelli, S., & Bennati, C. (2018) · Future Oncology · doi:10.2217/fon-2018-0095 · Cited by 17
The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC
Chen, L., Chi, F., Wang, T., Wang, N., Li, W., Liu, K., Shu, X. H., Ma, X., & Xu, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.009 · Cited by 15
Self-citationSima, N., Sun, W., Gorshkov, K., Shen, M., Huang, W., Zhu, W., Xie, X., Zheng, W., & Cheng, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.06.002 · Cited by 14
Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations
Chen, H., Hu, S., Patterson, A. V., Smaill, J. B., Ding, K., & Lu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00875 · Cited by 14
Structural Analysis of the Macrocyclic Inhibitor BI‐4020 Binding to EGFR Kinase
Beyett, T. S., Rana, J. K., Schaeffner, I. K., Heppner, D. E., & Eck, M. J. (2024) · ChemMedChem · doi:10.1002/cmdc.202300343 · Cited by 14
Self-citationFan, D., Zhang, H., Duan, L., Li, L., Xu, S., Tu, Y., Wang, L., Zheng, P., & Zhu, W. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107390 · Cited by 14
Pal, R., Matada, G. S. P., Teli, G., Chawla, V., & Chawla, P. A. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.141227 · Cited by 14
Wu, J., Wei, T., Tang, Q., Weng, B., Li, W., Jiang, X., Ding, T., Li, X., Liang, G., Cai, Y., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1307-9 · Cited by 14
Shao, J., Liu, S., Liu, X., Pan, Y., & Chen, W. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115680 · Cited by 14
Hu, L., Shen, D., Liang, D., Shi, J., Song, C., Jiang, K., Ren, M., Du, S., Cheng, W., Ma, J., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.023 · Cited by 14
Park, H., Jung, H.-Y., Kim, K., Kim, M., & Hong, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239323 · Cited by 14
Pei, J., Wang, G., Wang, A., Wu, C., Pan, X., Wen, S., Bu, F., Zhu, Y., Wang, Y., Ouyang, L., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00027 · Cited by 15
Huang, J., Huang, J., Wang, N., Wang, L., Li, L., Wang, C., Sun, X., Li, Y., Huang, G., & Ma, X. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102994 · Cited by 14
Toward structure-based drug design against the epidermal growth factor receptor (EGFR)
Haddad, Y., Remeš, M., Adam, V., & Heger, Z. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.007 · Cited by 14
Hao, Y., Lyu, J., Qu, R., Sun, D., Zhao, Z., Chen, Z., Ding, J., Xie, H., Xu, Y. F., & Li, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04184-9 · Cited by 14
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies
Damghani, T., Chitnis, S. P., Abidakun, O. A., Patel, K. B., Lin, K. S., Ouellette, E. A., Lantry, A. M., & Heppner, D. E. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01661 · Cited by 13
Li, Z., Ishida, R., Liu, Y., Wang, J., Li, Y., Gao, Y., Jiang, J., Che, J., Sheltzer, J. M., Robers, M. B., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114433 · Cited by 13
Self-citationExploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay
Xu, S., Duan, Y., Lou, L., Tang, F., Shou, J., & Wang, G. (2016) · Oncology Letters · doi:10.3892/ol.2016.5184 · Cited by 13
Fukuda, T., Anzai, M., Nakahara, A., Yamashita, K., Matsukura, K., Ishibashi, F., Oku, Y., Nishiya, N., Uehara, Y., & Iwao, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116039 · Cited by 13
Huang, B., Hao, M., Li, C., & Luo, K. Q. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106209 · Cited by 13
Predictive biomarkers in the management of EGFR mutant lung cancer
Rosell, R., Morán, T., Cardenal, F., Porta, R., Viteri, S., Molina‐Vila, M. Á., Benlloch, S., & Tarón, M. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05775.x · Cited by 13
Hong, Y., Jang, W., Chun, K., & Jeong, C. (2014) · Oncology Reports · doi:10.3892/or.2014.3161 · Cited by 13
Wang, C.-Y., Sun, Y., Zhu, X., Wu, B., Wang, Q., Zhen, Y., Shu, X. H., Liu, K., Zhou, Y., & Ma, X. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12692 · Cited by 13
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
Zhao, R., Zhou, S., Xia, B., Zhang, C., Hai, P., Hong, Z., & Wang, Y. (2016) · BMC Cancer · doi:10.1186/s12885-016-2519-3 · Cited by 13
Proto, C., Russo, G. L., Corrao, G., Ganzinelli, M., Facchinetti, F., Minari, R., Tiseo, M., & Garassino, M. C. (2017) · Tumori Journal · doi:10.5301/tj.5000663 · Cited by 14
Miller, M. M., & DelMonte, A. J. (2011) · Progress in heterocyclic chemistry · doi:10.1016/b978-0-08-096805-6.00013-9 · Cited by 13
Chen, L., Zhang, Y., Tian, L., Wang, C., Deng, T., Zheng, X., Wang, T., Li, Z., Tang, Z., Meng, Q., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113626 · Cited by 13
Self-citationThe Association of Annexin A1 and Chemosensitivity to Osimertinib in Lung Cancer Cells
Chuang, M., Lung, J., Chen, Y.-C., Lin, Y., Li, Y., & Hung, M. (2021) · Cancers · doi:10.3390/cancers13164106 · Cited by 13
Analysis of Conformational Determinants Underlying HSP90-Kinase Interaction
Kancha, R. K., Bartosch, N., & Duyster, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068394 · Cited by 13
Eldeeb, A. H., Shahin, M. I., Jaballah, M. Y., Elaraby, A. R., Ibrahim, T. M., Elaasser, M. M., Abdel‐Aziz, H. A., Lasheen, D. S., & Ella, D. A. A. E. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108899 · Cited by 12
Daguer, J., Zambaldo, C., Abegg, D., Barluenga, S., Tallant, C., Müller, S., Adibekian, A., & Winssinger, N. (2015) · Angewandte Chemie · doi:10.1002/ange.201412276 · Cited by 12
Yao, H., Ren, Y., Wu, F., Liu, J., Li, J., Cao, L., Yan, M., & Li, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116590 · Cited by 12
Costanzo, R., Montanino, A., Maïo, M. D., Piccirillo, M. C., Sandomenico, C., Giordano, P., Daniele, G., Franco, R., Perrone, F., Rocco, G., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.845092 · Cited by 12
Qin, Y., Long, Y., Tang, Y., Tian, Y., Li, J., Duan, P., Luo, J., Yu, M., Li, Y., Zhou, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15769 · Cited by 12
Wang, C., Wang, X., Wang, X., Tian, B., Zhang, S., Wang, T., Ma, Y., & Fan, Y. L. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107004 · Cited by 12
Zhang, J., Jia, J., Zhu, F., Ma, X., Han, B., Wei, X., Tan, C., Jiang, Y., & Chen, Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb25165e · Cited by 12
Zhang, B., Jiao, J., Liu, Y., Guo, L.-X., Zhou, B., Li, G., Yao, Z., & Zhou, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048748 · Cited by 12
Sato, T., Watanabe, H., Tsuganezawa, K., Yuki, H., Mikuni, J., Yoshikawa, S., Kukimoto‐Niino, M., Fujimoto, T., Terazawa, Y., Wakiyama, M., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.042 · Cited by 12
Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome
Looyenga, B. D., Cherni, I., MacKeigan, J. P., & Weiss, G. J. (2011) · Translational Oncology · doi:10.1593/tlo.10241 · Cited by 12
Ito, K., Nishio, M., Kato, M., Murakami, H., Aoyagi, Y., Ohe, Y., Okayama, T., Hashimoto, A., Ohsawa, H., Tanaka, G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0645 · Cited by 12
Li, C., Liu, W., Ning, J.-F., Meng, W.-Q., Hu, J., Zhao, Y., & Liu, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85357 · Cited by 12
Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer
Wang, D. D., Lee, V. H.-F., Zhu, G., Zou, B., Ma, L., & Yan, H. (2016) · Molecular BioSystems · doi:10.1039/c6mb00038j · Cited by 12
Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer
Rossi, A., Muscarella, L. A., Micco, C. D., Carbonelli, C. M., D’Alessandro, V., Notarangelo, S., Palomba, G., Sanpaolo, G., Taurchini, M., Graziano, P., et al. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1401064 · Cited by 12
Jangra, N., Sharma, B., Kumar, D., & Kapoor, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00799a · Cited by 11
Fu, J., Yu, J., Zhang, X., Chang, Y., Fan, H., Dong, M., Li, M., Liu, Y., & Hu, J. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2205605 · Cited by 11
Yang, S. H. (2013) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2013.75.5.188 · Cited by 11
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma
Bayraktar, S. (2013) · World Journal of Clinical Oncology · doi:10.5306/wjco.v4.i2.29 · Cited by 11
Mortlock, A. A., Foote, K. M., Kettle, J. G., & Aquila, B. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.11033-9 · Cited by 13
Osimertinib for the treatment of non-small cell lung cancer
Sun, J., Lee, S., Ahn, J. S., Park, K., & Ahn, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285283 · Cited by 11
Qin, X., Liu, P., Li, Y., Hu, L., Liao, Y.-X., Cao, T., & Yang, L. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129104 · Cited by 11
Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 – 2013)
Norman, P. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.936381 · Cited by 11
Zhang, H., Zhan, C., Ke, J., Xue, Z., Zhang, A., Xu, K., Shen, Z., Yu, L., & Chen, L. (2015) · Oncotarget · doi:10.18632/oncotarget.6491 · Cited by 11
Self-citationMao, L., Tang, W., Zhang, X., Liu, J., Chen, Y., Hua, Y., Weng, B., Mo, X., Bao, Y., Li, T., et al. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100035 · Cited by 11
Chen, L., Zhang, Y., Wang, C., Tang, Z., Meng, Q., Sun, H., Qi, Y., Ma, X., Li, L., Li, Y., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105045 · Cited by 11
Self-citationA novel treatment strategy for EGFR mutant NSCLC with T790M‐mediated acquired resistance
Taube, E., Jokinen, E., Koivunen, P., & Koivunen, J. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26461 · Cited by 11
Abou‐Seri, S. M., Farag, N. A., & Hassan, G. S. (2011) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.59.1124 · Cited by 11
Hennessy, E. J., Chuaqui, C. E., Ashton, S. E., Colclough, N., Cross, D. A. E., Debreczeni, J. E., Eberlein, C., Gingipalli, L., Klinowska, T. C. M., Orme, J. P., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00058 · Cited by 11
Nishiya, N. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.409 · Cited by 11
Akher, F. B., Farrokhzadeh, A., Ravenscroft, N., & Kuttel, M. M. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c03440 · Cited by 11
Pterisolic Acid B is a Nrf2 Activator by Targeting C171 within Keap1-BTB Domain
Dong, T., Liu, W., Shen, Z., Li, L., Chen, S., & Lei, X. (2016) · Scientific Reports · doi:10.1038/srep19231 · Cited by 11
Ji, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01629.x · Cited by 11
DNA encoded peptide library for SARS-CoV-2 3CL protease covalent inhibitor discovery and profiling
Xing, Y., Zhang, H., Wang, Y., Zong, Z., Bogyo, M. S., & Chen, S. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00097h · Cited by 10
Wang, Q., Zhu, Y., & Pei, J. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2389764 · Cited by 10
Metadata
- Authors
- Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., Engen, J. R., Wong, K.-K., Eck, M. J., Gray, N. S., & Jänne, P. A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Northeastern University (US)
- Corresponding author
- Gray, Nathanael S.
- ORCID
- Venue
- Nature
- Published
- 2009-12
- Volume
- 462
- Issue
- 7276
- Pages
- 1070-1074
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2879581
- OpenAlex
- W2133963438
- Cited by
- 1,013
- References
- 30
- Citations by year
- 2026: 32 · 2025: 43 · 2024: 39 · 2023: 60 · 2022: 46 · 2021: 55 · 2020: 62 · 2019: 55 · 2018: 66 · 2017: 84 · 2016: 82 · 2015: 75 · 2014: 71 · 2013: 82 · 2012: 54
- FWCI
- 45.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (R01AG2400401)
- National Cancer Institute (R01CA116020, R01CA122794, R01CA130876, R01CA11446, P50CA090578, R01CA135257, R01CA080942)
- National Institute of General Medical Sciences (R01GM070590)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- EGFR kinase inhibitors, mutant-selective inhibitors, irreversible kinase inhibitors, non-small cell lung cancer, drug resistance, co-crystallization, gatekeeper mutation
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Lung, Models, Chemical, Models, Molecular, Mutation, Phosphorylation, Drug Resistance, Neoplasm, NIH 3T3 Cells, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
